Could a constipation drug help keep colorectal cancer at bay?

NCT ID NCT07405736

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing whether adding lubiprostone, a drug usually used for constipation, to standard maintenance therapy can delay cancer recurrence in adults with colorectal cancer that has spread to the lining of the abdomen. About 124 participants who have had surgery will be randomly assigned to receive either maintenance therapy alone or with lubiprostone. The study aims to see if the combination improves progression-free survival at one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lubiprostone
What this could lead to
If it works, this could point toward a new way to delay cancer recurrence in patients with peritoneal metastatic colorectal cancer.
What could go wrong
This is an early phase II trial with only 124 participants, so results may not apply broadly. Lubiprostone is typically used for constipation, and its long-term safety for cancer patients is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.